Rezolute (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
$3.12
-$0.34(-6.35%)
At close: 4:00 PM EST
$3.12
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$1.07 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)2.90M
Market Cap
$298.58M
Enterprise Value$287.92M
Total Cash (Recent Filing)$132.94M
Total Debt (Recent Filing)$1.28M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding95,697,685
10 Day Avg. Volume4,110,039
30 Day Avg. Volume2,904,935
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.19K
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$5.00Price Target Upside60.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory EngagementAnalyst notes FDA receptivity to reviewing comprehensive study reports and datasets, indicating the agency may consider the submitted data for regulatory decisions without requiring a new controlled trial.
Tumor Indication Clinical ActivityExpanded access and early tumor patient data showed many patients discontinued intravenous dextrose or nutritional support after treatment, supporting clinical activity and the viability of a single-arm tumor study design.
Unmet Medical Need And MechanismErsodetug's novel mechanism and supportive Phase two data target patients who fail diazoxide, offering a potential medical alternative that could reduce the need for near-total pancreatectomy and lower long-term diabetes risk.
Bears Say
Data Interpretation And Study EffectsAn unusually high placebo response, likely driven by intensive glucose monitoring and behavioral changes, obscured treatment-control differences and complicates interpretation of trial results.
Efficacy OutcomeThe pivotal sunRIZE Phase three trial missed its primary and key secondary endpoints, creating material uncertainty about the drug's efficacy in congenital hyperinsulinism and prompting analysts to remove that indication from valuation models.
Financial And Dilution RiskCompany has no product revenue and is likely to need additional capital, which could lead to shareholder dilution and increase financial pressure if fundraising terms are unfavorable.
Rezolute News
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $1.07 and its highest was $11.46 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $298.58M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Sep 10, 2026 which is in 158 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Feb 12, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.187 by -$0.033.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rezolute have?
Rezolute has 95,697,685 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.187. Following the earnings report the stock price went up 5.785%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (60.26% Upside)
$5.00 (60.26% Upside)
Blogger Sentiment
Neutral
RZLT Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 5.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.31%
12-Months-Change
Fundamentals
Return on Equity
-64.81%
Trailing 12-Months
Asset Growth
23.77%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$5.00
▲(60.26% Upside)
Technical Analysis
Ownership Overview
10.94% Insiders
39.48% Mutual Funds
29.11% Other Institutional Investors
9.24% Public Companies and
Individual Investors